Pi-Cardia, a company specializing in medical devices, has recently received approval from the U.S. Food and Drug Administration (FDA) for a new device aimed at reducing the risk of coronary obstructions during valve-in-valve transcatheter aortic valve replacement (TAVR) procedures. Named the Shortcut, this device is designed to address complications associated with valve replacements in TAVR procedures, specifically aiding in preventing coronary artery blockages by splitting aortic valve leaflets before a new valve is implanted. This clearance was announced by Pi-Cardia on September 30, and earlier in January, the Shortcut device had been granted the breakthrough device designation by the FDA.
The necessity for such a device arises from the complications faced during valve-in-valve procedures, which are performed when an initial TAVR device fails. TAVR is often preferred as it avoids the need for repeat or open-heart surgery. Despite its benefits, one significant risk of valve-in-valve procedures is the increased likelihood of blockages that can impede blood flow to the heart. These blockages are generally caused by the leaflets of the failing valve, which, if displaced during the procedure, can lead to coronary obstructions. Research indicates that about 2.6% of patients experience obstructions during these procedures, with rates going up to 7% with certain devices.
To mitigate these risks, different strategies and devices have been developed. For instance, the National Institutes of Health developed a device called Basilica, which was first reported in 2018. The Basilica device uses electrosurgery to split the leaflets, whereas Pi-Cardia’s Shortcut employs a mechanical blade for this purpose. While both devices aim to prevent coronary obstructions by modifying the failing valve leaflets, the Shortcut device is noted for its mechanical simplicity and the controlled nature of the procedure, which makes it potentially easier to adopt and teach to operators compared to techniques like electrosurgery which require high skill levels and experience.
The effectiveness of the Shortcut device was demonstrated in a pivotal study, which according to Martin Leon, director of the Center for Interventional Vascular Therapy at New York-Presbyterian and chair of the global steering committee for Shortcut studies, showed that the procedure is controlled, teachable, and can be integrated smoothly into the TAVR workflow without interruptions. This is particularly beneficial for patients at risk of coronary obstruction, ensuring they can be safely treated.
As TAVR devices are increasingly used for younger patients with longer life expectancies, the longevity of these valves is a growing concern since they might fail within the patients’ lifetimes. The possibility of performing a valve-in-valve procedure is a significant advancement as it allows for the replacement of the valve without additional surgeries. Larry Wood, the group president of TAVR and surgical structural heart at Edwards Lifesciences, highlighted at an investor event that valve-in-valve procedures are expected to become more prevalent over time due to these factors.
Following FDA approval, Pi-Cardia is preparing for a limited launch of the Shortcut device, establishing a dedicated commercial and clinical support team. Looking ahead, the company anticipates expanding its applications to include native and bicuspid valves, estimating that about 30% of future TAVR cases could require some form of leaflet modification to achieve optimal results safely.
This approval represents a significant advancement in the field of valve replacement therapy, potentially improving the safety and efficacy of TAVR procedures and offering better long-term outcomes for patients undergoing this less invasive form of heart surgery.
#FDA #authorizes #PiCardias #valveinvalve #TAVR #device
